Oncologic Outcomes of Cytoreductive Nephrectomy in Synchronous Metastatic Renal-Cell Carcinoma: A Single-Center Experience

Published:August 10, 2018DOI:



      To evaluate the prognostic role of cytoreductive nephrectomy (CN) in patients with synchronous metastatic renal-cell carcinoma (mRCC).

      Patients and Methods

      We analyzed the electronic medical records of 294 patients with synchronous mRCC treated at Samsung Medical Center from January 2005 to December 2015. Primary and secondary end points were overall survival (OS) and cancer-specific survival (CSS), respectively. OS and CSS were estimated by the Kaplan-Meier method and compared between patients with and without CN, particularly by performing 1:1 propensity score matching. Multivariate Cox regression analysis was used to identify independent predictors of survival outcomes.


      Among the overall population of synchronous mRCC patients, 189 patients (64.3%) underwent CN. Compared to mRCC patients without CN, those who underwent CN have a higher proportion of single metastasis (63.0% vs. 32.4%) and clear-cell histology (87.8% vs. 72.4%). In the matched cohort, the patients who underwent CN had better OS and CSS outcomes compared to those who did not undergo CN (median OS, 23.0 months vs. 11.0 months; P < .001; median CSS, 34.0 months vs. 14.0 months; P < .001). On multivariable analysis, undergoing CN, body mass index, and Heng risk score were found as significant predictive factors of both OS and CSS. In subgroup analyses stratified by Heng risk criteria, the patients who received CN had better OS and CSS in all risk groups.


      CN significantly improved survival outcomes in synchronous mRCC patients treated with targeted therapies and independently associated with prolonged survival, regardless of Heng risk criteria.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Genitourinary Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Jemal A.
        • Bray F.
        • Center M.M.
        • Ferlay J.
        • Ward E.
        • Forman D.
        Global cancer statistics.
        CA Cancer J Clin. 2011; 61: 69-90
        • Hollingsworth J.M.
        • Miller D.C.
        • Daignault S.
        • Hollenbeck B.K.
        Five-year survival after surgical treatment for kidney cancer: a population-based competing risk analysis.
        Cancer. 2007; 109: 1763-1768
        • Chow W.H.
        • Devesa S.S.
        Contemporary epidemiology of renal cell cancer.
        Cancer J. 2008; 14: 288-301
        • Aben K.K.
        • Luth T.K.
        • Janssen-Heijnen M.L.
        • Mulders P.F.
        • Kiemeney L.A.
        • van Spronsen D.J.
        No improvement in renal cell carcinoma survival: a population-based study in the Netherlands.
        Eur J Cancer. 2008; 44: 1701-1709
        • Motzer R.J.
        • Mazumdar M.
        • Bacik J.
        • Berg W.
        • Amsterdam A.
        • Ferrara J.
        Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.
        J Clin Oncol. 1999; 17: 2530-2540
        • Ljungberg B.
        • Cowan N.C.
        • Hanbury D.C.
        • et al.
        EAU guidelines on renal cell carcinoma: the 2010 update.
        Eur Urol. 2010; 58: 398-406
        • National Comprehensive Cancer Network
        NCCN clinical practice guidelines: kidney cancer. Version 1.2018.
        (Available at:)
        • Flanigan R.C.
        • Salmon S.E.
        • Blumenstein B.A.
        • et al.
        Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.
        N Engl J Med. 2001; 345: 1655-1659
        • Mickisch G.H.
        • Garin A.
        • van Poppel H.
        • et al.
        Radical nephrectomy plus interferon-alfa–based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial.
        Lancet. 2001; 358: 966-970
        • Flanigan R.C.
        • Mickisch G.
        • Sylvester R.
        • Tangen C.
        • Van Poppel H.
        • Crawford E.D.
        Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis.
        J Urol. 2004; 171: 1071-1076
        • US Food and Drug Administration
        • Center for Drug Evaluation and Research Approval
        Package for application number NDA 21-923.
        (Available at:)
        • Motzer R.J.
        • Hutson T.E.
        • Tomczak P.
        • et al.
        Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.
        N Engl J Med. 2007; 356: 115-124
        • Abel E.J.
        • Culp S.H.
        • Tannir N.M.
        • et al.
        Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma.
        Eur Urol. 2011; 59: 10-15
        • Escudier B.
        • Eisen T.
        • Stadler W.M.
        • et al.
        Sorafenib in advanced clear-cell renal-cell carcinoma.
        N Engl J Med. 2007; 356: 125-134
        • Hudes G.
        • Carducci M.
        • Tomczak P.
        • et al.
        Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.
        N Engl J Med. 2007; 356: 2271-2281
        • Bex A.
        • Ljungberg B.
        • van Poppel H.
        • Powles T.
        • European Association of Urology
        The role of cytoreductive nephrectomy: European Association of Urology recommendations in 2016.
        Eur Urol. 2016; 70: 901-905
        • Heng D.Y.
        • Wells J.C.
        • Rini B.I.
        • et al.
        Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
        Eur Urol. 2014; 66: 704-710
        • Choueiri T.K.
        • Xie W.
        • Kollmannsberger C.
        • et al.
        The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy.
        J Urol. 2011; 185: 60-66
        • Hanna N.
        • Sun M.
        • Meyer C.P.
        • et al.
        Survival analyses of patients with metastatic renal cancer treated with targeted therapy with or without cytoreductive nephrectomy: a National Cancer Data Base Study.
        J Clin Oncol. 2016; 34: 3267-3275
        • Culp S.H.
        • Tannir N.M.
        • Abel E.J.
        • et al.
        Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy?.
        Cancer. 2010; 116: 3378-3388
        • Abdollah F.
        • Sun M.
        • Thuret R.
        • et al.
        Mortality and morbidity after cytoreductive nephrectomy for metastatic renal cell carcinoma: a population-based study.
        Ann Surg Oncol. 2011; 18: 2988-2996
        • Mejean A.
        • Ravaud A.
        • Thezenas S.
        • et al.
        Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma.
        N Engl J Med. 2018; 379: 417-427
        • Mathieu R.
        • Pignot G.
        • Ingles A.
        • et al.
        Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features.
        Urol Oncol. 2015; 33 (339.e9-15)